Sort by
Keyphrases
Belatacept
100%
Immunosuppression
100%
Liver Transplant Recipients
100%
Phase II Randomized Study
100%
Tacrolimus
37%
Mycophenolate Mofetil
31%
High Dose
31%
Graft Loss
18%
Death Loss
12%
Basiliximab
12%
Exploratory Phase
12%
Phase II Trial
6%
Phase II Study
6%
Acute Rejection
6%
Group 15 Elements
6%
Demographic Characteristics
6%
Corticosteroids
6%
Post-transplant Lymphoproliferative Disorder
6%
Immunosuppressive Regimens
6%
Number of Deaths
6%
Progressive multifocal Leukoencephalopathy
6%
Medicine and Dentistry
Immunosuppressive Treatment
100%
Liver Graft
100%
Belatacept
100%
Tacrolimus
37%
Drug Megadose
31%
Mycophenolate Mofetil
31%
Low Drug Dose
18%
Graft Failure
18%
Basiliximab
12%
Phase II Trials
6%
Posttransplant Lymphoproliferative Disease
6%
Acute Graft Rejection
6%
Progressive Multifocal Leukoencephalopathy
6%
Immunosuppressive Drug
6%
Nursing and Health Professions
Liver Graft
100%
Immunosuppressive Treatment
100%
Belatacept
100%
Tacrolimus
37%
Drug Megadose
31%
Mycophenolate Mofetil
31%
Low Drug Dose
18%
Graft Failure
18%
Basiliximab
12%
Immunosuppressive Agent
6%
Acute Graft Rejection
6%
Posttransplant Lymphoproliferative Disease
6%
Progressive Multifocal Leukoencephalopathy
6%
Efficacy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Belatacept
100%
Tacrolimus
37%
Mycophenolate Mofetil
31%
Graft Failure
18%
Basiliximab
12%
Phase II Trials
6%
Acute Graft Rejection
6%
Immunosuppressive Agent
6%
Posttransplant Lymphoproliferative Disease
6%
Progressive Multifocal Leukoencephalopathy
6%
Biochemistry, Genetics and Molecular Biology
Belatacept
100%
Drug Megadose
31%
Low Drug Dose
18%
Phase II Trials
6%